10:32 AM EST - Aurinia Pharmaceuticals Inc. : Announced that clinical data from its AURORA Phase 3 trial will be highlighted in a late-breaking oral presentation during the National Kidney Foundation 2020 Spring Clinical Meetings, which will be held as a live-virtual meeting per recommendations by the Centers for Disease Control and Prevention. The AURORA pivotal trial evaluated voclosporin in combination with mycophenolate and low-dose corticosteroids for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc.
shares T.AUP are trading down $0.60 at $16.33.
